Dr. Guy Boivin is a professor in the Department of Pediatric of the Faculty of Medicine at Laval University. He held the Canada Research Chair in Emerging Viruses and Antiviral Resistance during 14 years, as well as a « Foundation » grant from the Canadian Institutes of Health Research (CIHR) for 7 years. He is also co-principal investigator of major grants, such as the FPQIS ($ 12M), for the development of new generation influenza vaccines in the elderly. 

Dr. Boivin is the author or co-author of over 400 scientific publications and 390 presentations at various international conferences and symposia. He has also contributed to the creation of 17 patents and is co-founder of the company Signia Therapeutics, specializing in the repositioning of drugs to counter viral respiratory infections and of the company Vaxxel, that develops vaccines against respiratory viruses. He is the director of a NC3 laboratory that is operational since 2020, which expands the various research projects to highly pathogenic respiratory viruses, such as avian influenza viruses (H5N1, H7N9) and other emerging respiratory viruses. (SARS-CoV-2). He is also the co-director of the international lab RespiVir jointly with Dr Rosa-Calatrava from Lyon, France. 

His research program focuses on the pathogenesis, treatment and prevention of viral infections. He studies herpetic and respiratory viruses, including those causing the flu (human and avian flu). More recently, he has also been interested in SARS-CoV-2 responsible for COVID-19 and the Zika virus. He uses cell and molecular biology technologies, as well as different animal models to evaluate new antiviral molecules, elucidate mechanisms of resistance to antiviral agents, and generate new vaccines. He has completed several multicenter studies to assess the clinical and epidemiological impact of emerging respiratory viruses. He collaborates with several fundamental and clinical research groups as well as various pharmaceutical companies. His work has already had a significant impact on the diagnosis, treatment, and prevention of frequent and potentially life-threatening viral infections. 

CHUL
2705, boulevard Laurier
R-0709
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 47762 / 48907+1 418-654-2715
guy.boivin@crchudequebec....

Latest news

390 entries « ‹ 1 of 39 › »

Pageau G, Levasseur M, Paniconi T, Jubinville E, Goulet-Beaulieu V, Boivin G, Jean J

The possibility of spreading herpes simplex virus type 1 via food handling and sharing

Journal Article

J Appl Microbiol, 134 (10), 2023.

Abstract | Links:

Ghesquiere L, Boivin G, Demuth B, Giguere Y, Forest JC, Hamelin ME, Muckle G, Carbonneau J, Bujold E

Impact of COVID-19 and vaccination during pregnancy on placenta-mediated complications (COVIGRO study)

Journal Article

J Obstet Gynaecol Can, 2023.

Abstract | Links:

Côté F, Boivin G, Loungnarath V, Ruest A, Bestman-Smith J, Carbonneau J, Hamelin MÈ, Roy MC

Duration of isolation and contagiousness in coronavirus disease 2019 (COVID-19) patients receiving tocilizumab and dexamethasone: A case series

Journal Article

Infect Control Hosp Epidemiol, 44 (4), 2023.

Abstract | Links:

Royston L, Isnard S, Berini CA, Bu S, Lakatos PL, Bessissow T, Chomont N, Klein M, Lebouché B, de Pokomandy A, Kronfli N, Costiniuk CT, Thomas R, Tremblay C, Boivin G, Routy JP

Influence of letermovir treatment on gut inflammation in people living with HIV on antiretroviral therapy: protocol of the open-label controlled randomised CIAO study

Journal Article

BMJ Open, 13 (1), 2023.

Abstract | Links:

Zinszer K, Charland K, Pierce L, Saucier A, McKinnon B, Hamelin MÈ, Cheriet I, Da Torre MB, Carbonneau J, Nguyen CT, De Serres G, Papenburg J, Boivin G, Quach C

Pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and teenagers in Montréal, Canada

Journal Article

Int J Infect Dis, 131 , 2023.

Abstract | Links:

Eccles R, Boivin G, Cowling BJ, Pavia A, Selvarangan R

Treatment of COVID-19 symptoms with over the counter (OTC) medicines used for treatment of common cold and flu

Journal Article

Clin Infect Pract, 19 , 2023.

Abstract | Links:

Hénaut M, Carbonneau J, Rhéaume C, Levade I, Boivin G

In vitro fitness of SARS-CoV-2 variants as assessed by competition experiments followed by ddRT-PCR and whole genome sequencing

Journal Article

J Clin Virol, 165 , 2023.

Abstract | Links:

Saim-Mamoun A, Carbonneau J, Rhéaume C, Abed Y, Boivin G

Viral Fitness of Baloxavir-Resistant Recombinant Influenza B/Victoria- and B/Yamagata-like Viruses Harboring the I38T PA Change, In Vitro, Ex Vivo and in Guinea Pigs

Journal Article

Microorganisms, 11 (5), 2023.

Abstract | Links:

Zinszer K, Charland K, Pierce L, Saucier A, Hamelin MÈ, Da Torre MB, Carbonneau J, Nguyen CT, De Serres G, Papenburg J, Boivin G, Quach C

Infection-induced seroconversion and seroprevalence of SARS-CoV-2 among a cohort of children and youth in Montreal, Canada

Journal Article

Influenza Other Respir Viruses, 17 (8), 2023.

Abstract | Links:

Lamothe G, Carbonneau J, Joly Beauparlant C, Vincent T, Quessy P, Guedon A, Kobinger G, Lemay JF, Boivin G, Droit A, Turgeon N, Tremblay JP

Rapid and Technically Simple Detection of SARS-CoV-2 Variants Using CRISPR Cas12 and Cas13

Journal Article

CRISPR J, 6 (4), 2023.

Abstract | Links:

390 entries « ‹ 1 of 39 › »
Signaler des ajouts ou des modifications

Active projects

  • Antiviral Resistance and Benefits of Combination Therapy for Influenza Viruses, from 2023-03-01 to 2024-02-29
  • Changement de paradigme dans la conduite d'essais cliniques, from 2021-04-01 to 2024-03-31
  • CHOIR study: Children and Older Teens Immune Response to SARS-CoV-2 in Montreal, from 2021-12-01 to 2024-03-31
  • Évaluation des interactions entre des virus respiratoires, from 2022-02-01 to 2025-01-31
  • Identification of innate immune pathways as targets for immunomodulatory therapy in herpes simplex virus encephalitis, from 2023-10-01 to 2028-09-30
  • Innovative therapeutic approaches for the 2019-novel coronavirus, from 2021-03-01 to 2024-03-31
  • Laboratoire international associé (LIA) sur la pathogenèse, le traitement et la prévention des infections virales respiratoires (LIA RespiVIR), from 2021-07-27 to 2026-07-26
  • Manufacturing of antigens and adjuvants for development of vaccines (MAAV), from 2021-07-01 to 2024-03-31
  • Plateforme de laboratoire de niveau de confinement 3 pour la recherche sur les virus émergents, from 2023-01-31 to 2025-03-31
  • Relationship between COVID-19 and Parkinson’s disease in a mouse model, from 2022-10-01 to 2024-03-31

Recently finished projects

  • A research program on the pathogenesis, treatment and prevention of respiratory and herpes viruses, from 2016-07-01 to 2023-06-30
  • Canadian Immunization Research Network, from 2014-06-01 to 2021-12-31
  • COVIGRO : Impact de la COVID-19 et du vaccin contre SARS-CoV-2 sur le développement placentaire et foetal, from 2021-12-01 to 2022-11-30
  • Évaluation de l'efficacité des probiotiques sur les affections post-COVID-19. , from 2021-06-01 to 2022-03-31
  • Évaluation du potentiel thérapeutique de la protectine DX et d'analogues contre la COVID-19 , from 2020-06-01 to 2022-03-31
  • Hospital-based surveillance of influenza and routine monitoring of seasonal influenza vaccine effectiveness (VE), from 2020-11-01 to 2022-09-30
  • How to better manage infectious diseases in ER by triage with molecular mini-panels for the rapid detection of highly transmissible pathogens, from 2018-10-01 to 2022-09-30
  • Modulation des réponses immunitaires à la vaccination contre la COVID-19 par une intervention sur le microbiote intestinal : un essai randomisé contrôlé, from 2021-04-01 to 2022-03-31
  • Plateforme de laboratoire de niveau de confinement 3 respiratoire, from 2020-03-25 to 2022-03-27
  • Projet du Groupe québécois de recherche sur l'infection périnatale à COVID-19 (Banque de données des grossesses COVID-19), from 2020-04-01 to 2022-03-31
  • Sentinel Surveillance for Severe Outcomes of Laboratory-Confirmed Influenza in Adults for the Annual Influenza Season and for Confirmed and Suspected Cases Of Covid-19/Sars-Cov-2 Acute Respiratory Disease, Covid-19 Vaccine Effectiveness and, from 2022-04-01 to 2023-03-31
  • Sentinel surveillance, viral shedding, clinical characteristics and outcomes of confirmed and suspected hospitalized cases of COVID-19/SARS-CoV-2 infection in the Canadian Immunization Research Network (CIRN), from 2020-04-01 to 2022-03-31
  • SO05 QC07, Sentinel surveillance for confirmed and suspected cases of covid-19/covsars-2 acute respiratory disease, covid-19 vaccine effectiveness and adverse events following sars-cv-2 vaccines: A study of the Serious Outcomes Surveillance, from 2021-04-01 to 2023-09-30
Data provided by the Université Laval research projects registery